The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Adam J. Fein, Ph.D.
Drug Channels Institute

March 2020

Full report available at https://drugch.nl/pharmacy


**LICENSE TERMS**

This report is protected by copyright law. Unauthorized reproduction or distribution of this report or any portion of it may result in severe civil and criminal penalties and will be prosecuted to the maximum extent of the law. This report may be cited in commercial documents with full and appropriate attribution. Nothing in the license is intended to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws.

If you would like to quote from or otherwise cite the report, here is a suggested sample citation:


The complete End User License Agreement is available at: https://drugch.nl/2020EULA
ABOUT THE AUTHOR

Adam J. Fein, Ph.D., is the CEO of Drug Channels Institute (DCI), a leading management educator for and about the pharmaceutical industry. DCI is a subsidiary of Pembroke Consulting, Inc.

Dr. Fein is one of the country’s foremost experts on pharmaceutical economics and the drug distribution system. He has published hundreds of academic and industry articles, and is regularly quoted in such national publications as The Wall Street Journal, The New York Times, The Washington Post, Forbes, and many others.

His popular and influential Drug Channels website is the go-to source for definitive and comprehensive industry analysis, delivered with a witty edge. Drug Channels is the only place where you’ll find a serious discussion of PBMs, drug pricing, and pharmacy economics, all explained with humor and a healthy dose of pop culture.

Dr. Fein earned his doctoral degree from the Wharton School of Business at the University of Pennsylvania and his undergraduate degree from Brandeis University. He lives in Philadelphia with his wife, Paula, and their two children.

Contact information
Adam J. Fein, Ph.D.
Drug Channels Institute
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700
Website: www.DrugChannelsInstitute.com
Email: afein@drugchannels.net

Visit Dr. Fein’s Drug Channels website for the latest industry updates!

www.DrugChannels.net
Drug Channels Institute (DCI), a division of Pembroke Consulting, Inc., is a leading provider of specialized management education for and about the pharmaceutical industry.

In 2020, Drug Channels Institute will launch a new series of online training videos. They will combine Dr. Fein’s expertise and cutting-edge analysis—such as this 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers—into training videos that will offer your team a thorough grounding in crucial industry topics. These online tools will explain highly complex economic and business data and concepts so that you can:

- Make decisions that will best achieve your business goals
- Improve relationships with key accounts
- Understand your customers, channels, partners, and the economics of the U.S. pharmaceutical industry

Drug Channels Institute also hosts live webinars during which Dr. Fein discusses trends and policies that affect the pharmaceutical industry and its channels.

- [Click here to view our current and previous webinars.](#)
- [Click here to subscribe to Dr. Fein’s Drug Channels blog](#) and receive webinar announcements via email.

To learn more about how Drug Channels Institute can help your business, please contact:

Paula Fein, M.S.Ed.
V.P., Business Development
Drug Channels Institute
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700 x11
Website: [www.drugchannelsinstitute.com](http://www.drugchannelsinstitute.com)
Email: paula@drugchannelsinstitute.com
INTRODUCTION AND GUIDE TO THE 2020 REPORT

U.S. drug channels experienced an eventful 2019. The industry is confronting a diverse set of business, political, and legal challenges, some of which have persisted for years:

- Total prescription dispensing revenues of retail, mail, long-term care, and specialty pharmacies reached a record $446 billion in 2019. Specialty drugs accounted for 36% of these revenues—a new high for the industry.

- The largest insurers, PBMs, and specialty pharmacies have combined into vertically integrated organizations. They are poised to restructure U.S. drug channels by exerting greater control over patient access, sites of care, dispensing locations, and pricing.

- The specialty pharmacy industry continues to consolidate. UnitedHealth Group’s OptumRx business has acquired the two largest independent specialty pharmacies: Diplomat Pharmacy and Avella Specialty Pharmacy.

- Payers and PBMs are tightening their management of specialty drugs, which is pressuring independent specialty pharmacies, physician practices, and hospitals.

- Retail pharmacies have experienced slowing growth, lower profits, and mounting competitive pressures. The U.S. pharmacy industry has entered a shakeout process that will ultimately reduce the number of U.S. pharmacy locations.

- List prices for brand-name drugs are growing at rates that are slower than historical norms. Deflation in generic drug prices continues, though the rate of change has steadied. Politicians continue to condemn increasing drug prices, though brand-name drugs’ net prices (after rebates and discounts) are declining.

- The gross-to-net bubble, which measures rebates and discounts paid by manufacturers, reached $175 billion in 2019. More people now face pharmacy benefit designs with coinsurance and deductibles. This development is raising awareness about the harm of basing patients’ out-of-pocket expenses on undiscounted list prices.

- Regulators, lawmakers, investors, and payers are publicly scrutinizing PBMs’ profit models. New disclosures about PBMs’ unexpectedly large profits in Managed Medicaid programs have triggered some states to reevaluate PBMs’ role and compensation.

- Outside investors have accelerated their pursuit of prescription dispensing. Amazon is still signaling that it wants to become a major participant in the pharmacy market, though its market share remains trivial. Venture capital firms are financing technology-enabled pharmacies that are attempting to alter traditional ways of doing business.
• The federal government and multiple states are pursuing new policies aimed at introducing the commercial importation of drugs intended for foreign markets.

• Regulatory efforts to remove the role of rebates in the drug channel system have failed. The prospects of federal legislative action regarding drug prices or the channel remain highly uncertain.

Understanding an Evolving Marketplace

The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers—our 11th edition—remains the most comprehensive, fact-based tool for understanding the entire U.S. drug pricing, reimbursement, and dispensing system. This unique resource is your ultimate guide to the complex web of interactions within U.S. prescription drug channels.

This definitive, nonpartisan resource includes the most current information about pharmacy dispensing channels, third-party payers, pharmacy benefit managers (PBMs), patients’ financial contributions, government regulations, and more. The report synthesizes a wealth of statistical data, research studies, financial information, and my own unique business consulting experience. It will aid pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospital executives, pharmacy buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and many others.

Thousands of companies operate within the U.S. system, enabling more than 6.2 billion equivalent prescriptions to be dispensed and paid. The table below highlights the largest public companies that operate in the drug channel. Many of these firms are among the largest businesses on the Fortune 500 list.

Major Public Companies Operating in U.S. Drug Channels

<table>
<thead>
<tr>
<th>Company</th>
<th>Stock Ticker</th>
<th>Primary U.S. Channel Role(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS Health</td>
<td>CVS</td>
<td>Chain drugstore/PBM/Mail &amp; specialty pharmacy/Insurer</td>
</tr>
<tr>
<td>Kroger</td>
<td>KR</td>
<td>Supermarket with pharmacy/Specialty pharmacy</td>
</tr>
<tr>
<td>Rite Aid Corporation</td>
<td>RAD</td>
<td>Chain drugstore/PBM</td>
</tr>
<tr>
<td>Walgreens Boots Alliance</td>
<td>WBA</td>
<td>Chain drugstore/Mail &amp; specialty pharmacy</td>
</tr>
<tr>
<td>Walmart Stores, Inc.</td>
<td>WMT</td>
<td>Mass merchant with pharmacy/Specialty pharmacy</td>
</tr>
<tr>
<td>AmerisourceBergen Corp.</td>
<td>ABC</td>
<td>Pharmaceutical wholesaler/Specialty pharmacy</td>
</tr>
<tr>
<td>Cardinal Health, Inc.</td>
<td>CAH</td>
<td>Pharmaceutical wholesaler</td>
</tr>
<tr>
<td>McKesson Corporation</td>
<td>MCK</td>
<td>Pharmaceutical wholesaler/Specialty pharmacy</td>
</tr>
<tr>
<td>Express Scripts, Inc. (Cigna)</td>
<td>CI</td>
<td>PBM/Mail &amp; specialty pharmacy/Insurer</td>
</tr>
<tr>
<td>Humana Pharmacy Solutions</td>
<td>HUM</td>
<td>PBM/Mail &amp; specialty pharmacy/Insurer</td>
</tr>
<tr>
<td>OptumRx (UnitedHealth Group)</td>
<td>UNH</td>
<td>PBM/Mail &amp; specialty pharmacy/Insurer</td>
</tr>
</tbody>
</table>

PBM = pharmacy benefit manager
Source: Drug Channels Institute research

These and other companies discussed in this report operate within a complex distribution, payment, and reimbursement system, illustrated on the next page.
The U.S. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-Name Drugs

The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers discusses the three key channel flows illustrated above:

- **Product movement**, which traces shipments from pharmaceutical manufacturers to the drug wholesalers that supply pharmacies. Retail, mail, long-term care, and specialty pharmacies mark the final step in which a prescription is dispensed to a patient.

- **Financial flows**, which transfer money from third-party payers to pharmacy benefit managers (PBMs), which in turn reimburse pharmacies. Funds flow to manufacturers via pharmacies, which purchase drugs from wholesalers. Funds flow from manufacturers to PBMs in the form of rebates. The PBMs share most of these rebate payments with plan sponsors, reducing plans’ net prescription costs. Manufacturers’ rebates to PBMs and other third-party payers do not flow through wholesale or retail channels.

- **Contractual relationships**, which govern the relationships between: 1) payers and PBMs; 2) PBMs and pharmacies; 3) pharmacies and wholesalers; 4) wholesalers and manufacturers; and 5) manufacturers and PBMs.

In Sections II and III of the report, we revisit this chart to associate each flow with the corresponding report chapters that explain and analyze it. To further explain these flows and their corresponding report chapters, the chart appears as Exhibit 64 (page 100).
What’s New in the 2020 Report

The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers retains the overall structure that we introduced in last year’s edition. However, some sections and chapters have been expanded and/or reorganized to better cover the latest industry developments. As always, we have updated all market and industry data with the most current information available, including our annual analyses of the market positions of the largest pharmacies, specialty pharmacies, and PBMs. The many significant changes and updates in this 2020 edition include:

• Chapter 2 incorporates significant revisions to certain prescription data based on IQVIA’s revised methodologies for measuring demand.

• We have expanded the Chapter 3 analysis of the specialty market, including new data and additional information about industry participants.

• In Chapter 6, the data on patient out-of-pocket expenses include new information on cost sharing and average out-of-pocket spending.

• Chapter 9 contains a new section with information on third-party payers, rebates, and benefit designs. We have also expanded our discussion of PBMs’ evolving profit sources.

• We have further streamlined the material on wholesalers in Chapter 10. Our companion Economic Report on Pharmaceutical Wholesalers and Specialty Distributors contains a detailed analysis of this sector.

• Chapter 11 includes significant new information based on our analyses of newly disclosed data on the following topics:
  o PBMs’ profit from spread pricing in Managed Medicaid programs
  o Direct and indirect remuneration (DIR) fees paid by pharmacies
  o Pharmacies’ profits from the 340B Drug Pricing Program

• Chapter 12, which was introduced last year and covers the industry outlook and emerging trends, has been expanded. Notable additions include new material on:
  o Consequences of vertical integration among insurers, PBMs, specialty pharmacies, and providers
  o Commercial importation of drugs intended for foreign markets
  o State legislation of the drug channel
  o Specialty pharmacies’ role in cell and gene therapy channels

• Throughout the report, we have added new industry data sources, deepened our coverage of many topics, and added more trending information. There are 203 exhibits in the 2020 edition, compared with 180 in the 2019 edition.
Structure of the 2020 Report

This report analyzes the industry in 3 major sections, comprising 12 total chapters.

SECTION I: THE U.S. PHARMACY INDUSTRY

- **Chapter 1: Industry Overview** (page 9) defines the industry and its regulatory framework, describes the different products and prescriptions that a pharmacy dispenses, provides data on traditional and specialty prescription costs, delineates among different pharmacy industry participants, and quantifies differences among dispensing formats. This chapter includes our analysis of retail clinics and pharmacist-provided clinical services, including medication therapy management services.

- **Chapter 2: Pharmacy Industry Market Structure** (page 39) analyzes the industry’s prescription and revenue growth trends. It identifies the largest pharmacies based on prescription revenues. It then analyzes recent market share trends for each dispensing format and for the major national companies.

- **Chapter 3: Specialty Drugs and Specialty Pharmacies** (page 60) provides a comprehensive overview of the pharmacies dispensing specialty medications. It includes our exclusive analyses of national market share for pharmacy-dispensed specialty drugs and accreditation trends among pharmacies. It also provides a competitive analysis of the various organizations that compete to dispense specialty medications. The chapter reviews the channel strategies that pharmaceutical manufacturers use for specialty drugs, explains the role of service fees, and reviews the specialty hub services market.

SECTION II: THIRD-PARTY PAYMENT AND PHARMACY BENEFITS

- **Chapter 4: Payment and Spending for Prescription Drugs** (page 101) examines the primary payers for prescription drugs at retail, mail, long-term care, and specialty pharmacies. It analyzes recent changes in the payer mix and spending on traditional vs. specialty drugs. Chapter 4 also reviews the cash-pay prescription market and the use of discount card programs.

- **Chapter 5: Pharmacy Benefit Management** (page 119) identifies the services and roles of pharmacy benefit managers (PBMs). Chapter 5 also analyzes the structure of the PBM industry and reviews the business strategies of the largest PBMs. It describes the relationship between PBMs and the pharmacies that participate in a PBM’s network, reviews how pharmacy services administrative organizations (PSAOs) intermediate between retail pharmacies and PBMs, and explains how plan sponsors compensate PBMs for benefit management services.

- **Chapter 6: Consumer Copayments and Coinsurance** (page 146) analyzes the benefit designs and plan structures that determine patients’ out-of-pocket spending for the
major third-party payers: employer-sponsored health plans, Health Insurance Marketplace (HIM) plans, Medicare Part D, and Medicaid. We explore manufacturers’ out-of-pocket payment support programs, explain the emergence and use of copay accumulators, and provide data on patient out-of-pocket expenses. We also explore how benefit design affect patients’ costs.

- **Chapter 7: Narrow Pharmacy Networks** (page 176) analyzes the structure, utilization, and economics of narrow network models. We explain the use and economics of narrow networks for pharmacies in commercial health plans and Medicare Part D. We review the use of mail and retail pharmacies as narrow network options for maintenance prescriptions. This chapter also evaluates the latest data on payer-defined networks for specialty drug dispensing in commercial health plans and for buy-and-bill channels.

**SECTION III: DRUG CHANNEL ECONOMICS AND OUTLOOK**

- **Chapter 8: Prescription Reimbursement by Third-Party Payers** (page 201) explains the formulas and methodologies for computing a pharmacy’s revenue from brand-name, generic, and specialty prescriptions. This chapter compares traditional list price methods with acquisition-cost reimbursement approaches. We also review the economics of mail vs. retail pharmacies for payers and consumers.

- **Chapter 9: Drug Pricing, Rebates, and Payer Costs** (page 215) explores rebates in commercial health plans, Medicare Part D, and Medicaid. It explains how PBMs negotiate with manufacturers, analyzes trends in list and net drug prices, and describes the gross-to-net bubble phenomenon. The chapter includes a new section that explains how plan sponsors use rebates, the role of point-of-sale rebates, and controversies over rebates. The chapter concludes by illustrating how prescription reimbursement, formulary rebates, and consumer copayments affect a plan sponsor’s net costs for a typical traditional and specialty prescription.

- **Chapter 10: Relationships With Pharmaceutical Wholesalers** (page 244) explores pharmacies’ interactions with their primary wholesale suppliers of drugs. It explains wholesalers’ channel roles and services, identifies the largest wholesale suppliers, and analyzes how wholesalers affect pharmacies’ acquisition costs for drugs. We present our latest data on pharmacy group purchasing organizations and the generic sourcing relationships between wholesalers and large pharmacies.

- **Chapter 11: Pharmacy and Prescription Profitability** (page 256) unites the reimbursement and cost discussion from Chapter 8 and Chapter 10 by presenting the latest available data on pharmacy and prescription profitability. This chapter documents overall drugstore profitability, pharmacy margins for prescriptions from different dispensing formats, profit differences between brand and generic prescriptions, PBMs’ per-prescription profits from network and mail pharmacies, and a detailed review of
PBMs’ spread pricing profits from Managed Medicaid programs. Chapter 11 also includes material on the direct and indirect remuneration (DIR) fee payments that pharmacies make to PBMs and health plans. Finally, we consider pharmacies’ role and profits in the 340B Drug Pricing Program.

• Chapter 12: Outlook and Emerging Trends (page 288) presents the outlook for net prescription drug spending, the future payer mix, and our updated projections for the pharmacy industry’s product mix and revenues in 2024. This chapter also considers future trends, including pharmacy-dispensed biosimilars, importation, state and federal legislation, cell and gene therapies, and such new entrants as Amazon and venture-backed startup pharmacies.

How to Use the 2020 Report

The chapters are self-contained and do not need to be read in order. We include extensive internal clickable hyperlinks to help you navigate the entire document and customize it to your specific needs. After clicking a link, use the following shortcuts to return to your previous location in the document:

• Windows: ALT+Left Arrow
• Mac: Command+Left Arrow

There are more than 600 endnotes, most of which have hyperlinks to original source materials. The report also includes a list of the Acronyms and Abbreviations used within it. To search the entire PDF document for every occurrence of a word or phrase, use the following keyboard shortcuts:

• Windows: Shift+CTRL+F
• Mac: Shift+Command+F

As always, I welcome your feedback. Please contact me if you have any questions or comments about The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers.

Adam J. Fein
March 2020

P.S. Click here for post-publication errata.
# CONTENTS

**PREFACE: INDUSTRY TRENDS AND KEY REPORT THEMES** .................................................................................................................. 1

**SECTION I: THE U.S. PHARMACY INDUSTRY** .......................................................................................................................... 8

**Chapter 1: Industry Overview** ..................................................................................................................................................... 9

1.1. Pharmacy Fundamentals .................................................................................................................................................... 9

1.1.1. Defining the Practice of Pharmacy ............................................................................................................................... 9

1.1.2. Pharmacies and the Drug Supply Chain Security Act .................................................................................................. 10

1.2. The Products That Pharmacies Dispense ....................................................................................................................... 13

1.2.1. Brand vs. Generic Drugs ................................................................................................................................................. 13

1.2.2. Traditional vs. Specialty Drugs ..................................................................................................................................... 15

1.2.3. Top Therapy Classes and Average Prescription Costs ............................................................................................... 18

1.3. Pharmacy Industry Participants ......................................................................................................................................... 20

1.3.1. Pharmacy Dispensing Formats .................................................................................................................................... 20

1.3.2. Differences Among Outpatient Retail Dispensing Formats .......................................................................................... 22

1.3.3. Pharmacist Salaries and Employment ........................................................................................................................... 26

1.4. Healthcare and Clinical Services ........................................................................................................................................ 29

1.4.1. Retail Clinics ...................................................................................................................................................................... 29

1.4.2. Medication Therapy Management (MTM), Clinical Services, and Provider Status ..................................................... 33

1.4.3. Immunization .................................................................................................................................................................... 37

**Chapter 2: Pharmacy Industry Market Structure** .................................................................................................................. 39

2.1. Industry Trends ......................................................................................................................................................................... 39

2.1.1. Total and 30-Day Equivalent Prescriptions ................................................................................................................... 39

2.1.2. Prescription Dispensing Revenues ................................................................................................................................ 42

2.2. National Prescription Dispensing Market Share, by Company ........................................................................................... 43

2.3. Trends by Dispensing Format ............................................................................................................................................... 44

2.3.1. Revenues, Prescriptions, and Number of Pharmacies: Five-Year Trends ....................................................................... 44

2.3.2. Market Changes in 2019 .................................................................................................................................................... 46

2.3.3. National Retail Chains ......................................................................................................................................................... 47

2.3.4. Regional Drugstore Chains ............................................................................................................................................... 53

2.3.5. Independent Pharmacies .................................................................................................................................................. 54
Chapter 6: Consumer Copayments and Coinsurance

6.1. Cost Sharing in Pharmacy Benefit Design ................................................................. 146
   6.1.1. Employer-Sponsored Health Plans ................................................................. 147
   6.1.2. Health Insurance Marketplace Plans ............................................................. 153
   6.1.3. Medicare Part D ................................................................................................. 155
   6.1.4. Medicaid ........................................................................................................... 161
6.2. Manufacturer Out-of-Pocket Payment Support ......................................................... 162
   6.2.1. Copayment Offset Programs ........................................................................... 162
   6.2.2. Copay Accumulator and Maximizer Programs ............................................... 166
   6.2.3. Patient Assistance Programs .......................................................................... 168
6.3. Out-of-Pocket Expenses ............................................................................................................. 169
6.3.1. Actual Patient Out-of-Pocket Spending on Prescriptions .................................................... 169
6.3.2. Consequences of Pharmacy Benefit Designs ........................................................................ 172

Chapter 7: Narrow Pharmacy Networks ...................................................................................... 176
7.1. Overview of Pharmacy Benefit Network Models ..................................................................... 176
7.1.1. Network Options .................................................................................................................. 176
7.1.2. The Economics of Narrow Pharmacy Networks ................................................................. 178
7.1.3. Legal and Regulatory Restrictions on Network Design ..................................................... 180
7.2. Retail Pharmacy Networks .................................................................................................... 181
7.2.1. Preferred Retail Networks in Medicare Part D ................................................................. 181
7.2.2. Narrow Retail Networks in Commercial and Other Plans .................................................. 189
7.2.3. Narrow Networks for Maintenance Prescriptions ............................................................. 191
7.3. Payer-Defined Specialty Dispensing Networks ........................................................................ 194
7.3.1. Commercial Health Plans .................................................................................................. 194
7.3.2. Specialty Pharmacies’ Role in Buy-and-Bill Channels ....................................................... 197

SECTION III: DRUG CHANNEL ECONOMICS AND OUTLOOK .................................................. 200

Chapter 8: Prescription Reimbursement by Third-Party Payers .................................................... 201
8.1. The Basics of Prescription Reimbursement ............................................................................. 201
8.1.1. Estimated Acquisition Cost (EAC) ....................................................................................... 201
8.1.2. Dispensing Fees .................................................................................................................. 203
8.1.3. Service and Data Fees ........................................................................................................ 204
8.2. Reimbursement for Brand-Name and Specialty Prescriptions .................................................. 204
8.2.1. Wholesale Acquisition Cost (WAC) and Average Wholesale Price (AWP) List Prices ......... 204
8.2.2. AWP Discounts for Pharmacy Reimbursement ................................................................. 205
8.2.3. Why Mail Pharmacies Accept Lower Reimbursements ..................................................... 208
8.3. Reimbursement for Generic Prescriptions ................................................................................ 209
8.3.1. Challenges for List-Price Benchmarks ................................................................................ 209
8.3.2. Maximum Allowable Cost (MAC) Limits and Generic Effective Rate (GER) ..................... 210
8.3.3. Regulations and Laws Regarding MAC Limits .................................................................... 211
8.3.4. Medicaid and Federal Upper Limits .................................................................................... 211
8.4. Acquisition Cost Reimbursement ............................................................................................ 212
Chapter 9: Drug Pricing, Rebates, and Payer Costs ................................................................. 215
  9.1. Rebates to Third-Party Payers ................................................................................... 215
    9.1.2. Rebates and DIR in Medicare Part D ................................................................. 220
    9.1.3. The Medicaid Drug Rebate Program ................................................................. 223
  9.2. Gross and Net Drug Pricing ...................................................................................... 226
    9.2.1. List vs. Net Drug Prices ..................................................................................... 226
    9.2.2. The Gross-to-Net Bubble ................................................................................... 229
  9.3. Issues with the Rebate System ................................................................................. 232
    9.3.1. How Plan Sponsors Use Rebates ...................................................................... 232
    9.3.2. Point-of-Sale (POS) Rebates ............................................................................. 233
    9.3.3. Controversies Over Rebates ............................................................................. 235
  9.4. How Prescription Reimbursement, Formulary Rebates, Consumer Copayments, and PBM Expenses Affect Plan Sponsor Costs ................................................................................................................. 238

Chapter 10: Relationships With Pharmaceutical Wholesalers ........................................ 244
  10.1. Overview of Wholesale Drug Channels ................................................................. 244
    10.1.1. Industry Participants ......................................................................................... 244
    10.1.2. Product Distribution ......................................................................................... 245
    10.1.3. Financial Intermediation ................................................................................. 246
    10.1.4. Other Services for Pharmacies, Providers, and Manufacturers ...................... 247
    10.1.5. Impact on Pharmacy Reimbursement ............................................................... 248
  10.2. Determinants of Pharmacies’ Acquisition Costs .................................................... 248
    10.2.1. Wholesaler Pricing of Brand-Name Drugs to Pharmacies .............................. 248
    10.2.2. Pharmacy Group Purchasing Organizations ................................................... 250
    10.2.3. Generic Sourcing Relationships Between Wholesalers and Large Pharmacies .......................................................... 252

Chapter 11: Pharmacy and Prescription Profitability ....................................................... 256
  11.1. Overall Drugstore Gross Margins .......................................................................... 256
    11.1.1. Industry Averages ............................................................................................ 256
    11.1.2. Chain Drugstores ............................................................................................ 258
  11.2. Pharmacy Per-Prescription Profits ....................................................................... 259
    11.2.1. Sources of Per-Prescription Profits ................................................................ 259
11.2.2. Average Per-Prescription Profits for Pharmacies ........................................... 260
11.2.3. PBM Per-Prescription Profits from Network and PBM-Owned Pharmacies .......... 263
11.2.4. The Impact of Brand-Name Inflation on Prescription Profits ........................... 267
11.2.5. Pharmacy Profits With Acquisition Cost-Based Reimbursement .................... 269
11.3. Lifecycle Profitability for Generic Prescriptions .................................................. 270
11.4. Pharmacy DIR Fees in Medicare Part D Networks ........................................... 273
  11.4.1. Computation of Pharmacy DIR Fees ......................................................... 274
  11.4.2. Financial Impact of Pharmacy DIR Fees ..................................................... 275
  11.4.3. The Outlook for Pharmacy DIR Fees ......................................................... 277
11.5. Pharmacy Profits from the 340B Drug Pricing Program ...................................... 278
  11.5.1. Overview of the 340B Program and Drug Prices ......................................... 279
  11.5.2. Companies Participating as 340B Contract Pharmacies ............................... 279
  11.5.3. Flow of Funds for a 340B Contract Pharmacy Network ............................... 283
  11.5.4. Pharmacy and Covered Entity Profits from 340B Prescriptions ..................... 285

Chapter 12: Outlook and Emerging Trends ............................................................... 288
  12.1. Industry Outlook ......................................................................................... 288
  12.1.1. U.S. Net Spending on Outpatient Prescriptions from 2019 to 2024 .................. 288
  12.1.2. Payment for Outpatient Prescription Drugs in 2024 .................................... 289
  12.1.3. Pharmacy Revenues from Traditional vs. Specialty Drugs in 2024 .................. 290
  12.2. Drug Prices .............................................................................................. 292
  12.2.1. The Outlook for Brand-Name Drug Prices ............................................... 292
  12.2.2. The Outlook for Generic Drug Prices ....................................................... 293
  12.3. The Outlook for Biosimilars ....................................................................... 299
  12.3.1. Update on the Biosimilar Market ............................................................... 299
  12.3.2. Biosimilars Under the Pharmacy Benefit .................................................. 300
  12.4. Emerging Trends ...................................................................................... 303
  12.4.1. Consequences of Vertical Integration ....................................................... 303
  12.4.2. Importation From Foreign Markets ......................................................... 305
  12.4.3. State Legislation of the Drug Channel ..................................................... 306
  12.4.4. Specialty Pharmacies’ Role in Cell and Gene Therapy Channels .................. 307
  12.4.5. The Outlook for the 340B Program .......................................................... 309
12.5. New Entrants and Potential Pharmacy Market Disruption................................................... 310
12.5.1. Update on Amazon’s Potential Impact ........................................................................... 310
12.5.2. Venture-Backed Online Pharmacies ............................................................................. 313

Acronyms and Abbreviations........................................................................................................ 315
Endnotes....................................................................................................................................... 316
LIST OF EXHIBITS

Exhibit 1: Timeline of DSCSA Requirements for Pharmacies (Dispensers), 2013 to 2023 ..................................................10
Exhibit 2: Unbranded and Branded Generics, Share of U.S. Prescriptions, 2003 to 2024 ..................................................13
Exhibit 3: Top Traditional Therapy Categories, Generic Drugs as a Share of Prescriptions and Net Spending, 2018 ..........................14
Exhibit 4: Specialty Prescriptions, Number and Share of Total, 2014 to 2019 .................................................................16
Exhibit 5: Top Specialty Therapy Categories, Generic Drugs as a Share of Prescriptions and Net Spending, 2018 ................18
Exhibit 6: Top Traditional Therapy Categories, Share of Net Spending and Average Net Prescription Costs, 2018 ........................................19
Exhibit 7: Top Specialty Therapy Categories, Share of Net Spending and Average Net Prescription Costs, 2018 ................19
Exhibit 8: Chain Drugstore Revenues, by Type of Merchandise, 2017 .................................................................22
Exhibit 9: Average Annual Number of Prescriptions per Pharmacy, by Retail Dispensing Format, 2019 23
Exhibit 10: Average Wait Time for Prescription Pickup, by Retail Dispensing Format, 2018 .................................24
Exhibit 11: Average Annual Prescription Revenue per Pharmacy Outlet, by Retail Dispensing Format, 2019 ........24
Exhibit 12: Top Four Reasons for Pharmacy Selection, by Dispensing Format ..........................................................25
Exhibit 13: Customer Satisfaction With Pharmacies, by Dispensing Format and Company, 2019 ...........................................26
Exhibit 14: Pharmacist Employment and Salary, by Employer, 2018 .................................................................26
Exhibit 15: Pharmacists, Change in Annual Average Salary, by Employer, 2014 to 2018 ..................27
Exhibit 16: Pharmacist Employment, by Industry and Dispensing Format, 2018 vs. 2028 ..........................................................28
Exhibit 17: Insurance Coverage for Retail Clinics, 2010 to 2019 .................................................................30
Exhibit 18: Number of U.S. Retail Clinics, 2004 to 2020 .................................................................30
Exhibit 19: Number of Retail Clinics, by Chain Location, 2020 .................................................................31
Exhibit 20: Providers of Medication Therapy Management Services, Medicare Part D, 2019 ..........................................................34
Exhibit 22: Adult Influenza Vaccination, by Place of Vaccination, 2012-13 vs. 2018-19 ..................................................37
Exhibit 23: Consumer Use of Immunization at Retail Pharmacies, by Dispensing Format, 2018 ..................................................38
Exhibit 24: Total U.S. Pharmacy Industry Prescription Revenues, Prescriptions, and Locations, by Dispensing Format, 2019 ..................................................39
Exhibit 25: Prescriptions, Annual Total and Growth, 2015 to 2019 .................................................................40
Exhibit 26: 30-Day Equivalent Prescriptions, Annual Total and Growth, 2015 to 2019 ..................................................40
Exhibit 27: 90-Day Prescriptions as a Percentage of Total Prescriptions, by Dispensing Format, 2019 ..................41
Exhibit 28: Pharmacy Industry Prescription Revenues, Annual Total and Growth, 2015 to 2019 ..................................................42
Exhibit 29: Largest 15 U.S. Pharmacies, by Total Prescription Revenues, 2019 .................................................................43
Exhibit 30: Total Change in 30-Day Equivalent Prescriptions Dispensed and Prescription Revenues, by Pharmacy Type, 2013 vs. 2019 ..................................................45
Exhibit 31: 30-Day Equivalent Prescriptions Dispensed per Location, by Dispensing Format, 2010 to 2019 ........45
Exhibit 32: Number of 30-Day Equivalent Prescriptions, by Dispensing Format, 2018 vs. 2019 ..................................................46
Exhibit 33: Prescription Dispensing Revenues, by Dispensing Format, 2018 vs. 2019 ..................................................47
Exhibit 34: Year-Over-Year Change in Same-Store Prescription Count, by Chain, 2016 to 2019 ...........................................48
Exhibit 35: Walgreens Boots Alliance, U.S. Store Count, 2016 to 2019 ..........................................................50
Exhibit 36: Largest Regional Chain Drugstores, by Total Prescription Revenues, 2019 ..............................................53
Exhibit 37: Number of Independent Pharmacies, 2001 to 2019 ............................................................................54
Exhibit 38: Pharmacy Franchise and Marketing Programs, 2019 ..............................................................................55
Exhibit 39: Share of Mail Pharmacy Dispensing Revenues, by Company, 2019 .................................................59
Exhibit 40: Importance of Specialty Pharmacy Services to Patients, 2018 ...........................................................62
Exhibit 41: Usage of Specialty Pharmacy Services by Patients, 2018 .................................................................63
Exhibit 42: Employer Perceptions of Specialty vs. Retail Pharmacies, 2017 .........................................................64
Exhibit 43: Specialty Prescription Dispensing Revenues, Annual Total and Growth, 2015 to 2019 .........................67
Exhibit 44: Specialty Drugs as a Percentage of Pharmacy Industry Prescription Revenues, 2013 to 2019 ..........67
Exhibit 45: Specialty Drugs as a Percentage of Payers’ Pharmacy Benefit Spending, by PBM, 2013 vs. 2018 ....68
Exhibit 46: Number of Pharmacy Locations With Specialty Pharmacy Accreditation, by Organization, 2015 to 2019 ..................................................................................................................................................69
Exhibit 47: Locations With URAC Specialty Pharmacy Accreditation, 2008 to 2019 ..............................................70
Exhibit 48: Prescription Revenues and Market Share from Specialty Pharmaceuticals, by Company, 2019 ..........70
Exhibit 49: Merger and Acquisition Transactions, Specialty Pharmacy and Infusion Services, 2014 to 2019 ....71
Exhibit 50: Pharmacy Locations With Specialty Pharmacy Accreditation, by Corporate Ownership, 2019 ........73
Exhibit 51: Share of Pharmacy Locations With Specialty Pharmacy Accreditation, by Corporate Ownership, 2015 vs. 2019 ..................................................................................................................................................74
Exhibit 52: Specialty Drug Prescription Revenues, by Dispensing Format, 2019 ..................................................75
Exhibit 53: Specialty Drug Spending, by Dispensing Channel and Therapeutic Class, 2018 ......................................76
Exhibit 54: Fastest-Growing Private Specialty Pharmacies, 2018 ...........................................................................79
Exhibit 55: Retail Companies With Specialty Pharmacy Businesses, 2019 .........................................................82
Exhibit 56: Hospitals With a Specialty Pharmacy, by Number of Staffed Beds, 2016 vs. 2018 .........................84
Exhibit 57: Prescription Dispensing Revenues from Specialty Pharmacy, by Health System, 2019 .................84
Exhibit 58: Hospital-Employed Physicians, 2012 to 2018 ....................................................................................87
Exhibit 59: Health Systems’ Requirements for Employee Use of an In-House Pharmacy, 2019 .........................87
Exhibit 60: Percentage of Oncology Practices With In-Practice Oral Oncology Drug Dispensing, 2013 to 2018 ..........89
Exhibit 61: Patient-Administered Oncology Volume, by Dispensing Channel, 2019 ............................................89
Exhibit 62: Frequency of Manufacturer Contracting for Specialty Pharmacy Services, by Type of Service, 2017 to 2019 ..................................................................................................................................................96
Exhibit 63: Leading Specialty Hub Services Providers, 2019 .................................................................................98
Exhibit 64: Chapter Coverage of Flows in the U.S. Distribution and Reimbursement System ..............................100
Exhibit 65: Health Insurance Enrollment, by Payer, 2008 vs. 2018 ....................................................................101
Exhibit 66: Share of U.S. National Health Expenditures, by Category, 2018 ......................................................103
Exhibit 67: Share of U.S. National Health Expenditures, by Major Spending Category, 1978 to 2018 .............104
Exhibit 68: Growth in U.S. National Health Expenditures, by Major Spending Category, 2010 to 2018 ..........104
Exhibit 69: Outpatient Prescription Drug Expenditures, by Source of Payment, 2018 .................................105
Exhibit 70: Outpatient Prescription Drugs as a Share of U.S. National Health Expenditures, by Payer, 2005 to 2018 .......................................................... 106
Exhibit 71: Outpatient Prescription Drug Dispensing, by Source of Payment, 2018 ........................................ 107
Exhibit 72: Prescription Expenses per Person, by Age, 2017 ........................................................................ 107
Exhibit 73: Change in Net Spending for Outpatient Prescription Drugs, by Payer, 2017 vs. 2018 ................ 108
Exhibit 74: Hospital Care vs. Prescription Drugs, Total Expenditures and Consumer Out-of-Pocket Spending, 2018 .................................................................................. 109
Exhibit 75: Change in Commercial Payer Net Drug Spending, Traditional vs. Specialty Drugs, 2014 to 2019 .... 110
Exhibit 76: Change in Commercial Payer Net Drug Spending, Traditional vs. Specialty Drugs, by PBM, 2018 ...... 111
Exhibit 77: Express Scripts, Change in Net Drug Spending, Traditional vs. Specialty Drugs, by Payer, 2018 .... 111
Exhibit 78: Components of Change in Net Commercial Payer Drug Spending, by PBM, 2018 ......................... 113
Exhibit 79: Components of Change in Net Specialty Drug Spending, by PBM, 2018 ....................................... 113
Exhibit 80: Cash-Pay Prescriptions as a Share of Total Prescriptions, 2017 to 2019 ..................................... 114
Exhibit 81: Relative Cash Prescription Prices for Generic and Brand-Name Drugs, by Dispensing Format, 2019.... 116
Exhibit 82: Pharmacy Benefit Management Contracting Approach, by Company Size, 2019 ......................... 121
Exhibit 83: Medicare Part D Plan Sponsor Contract Use of PBM, by Benefit Management Service, 2016 ........ 122
Exhibit 84: Number of Products on PBM Formulary Exclusion Lists, 2012 to 2020 ........................................ 125
Exhibit 85: Formulary Exclusions for Specialty Drugs, Medicare Part D Plans, 2019 ................................. 127
Exhibit 87: Prevalence of Utilization Management Tools, Medicare Part D Plans, 2019 ............................. 130
Exhibit 88: PBM Market Share, by Total Equivalent Prescription Claims Managed, 2019 ......................... 131
Exhibit 89: Vertical Business Relationships Among Insurers, PBMs, Specialty Pharmacies, and Providers, 2019 .... 136
Exhibit 90: Largest Pharmacy Services Administrative Organizations, by Members and Ownership, 2019 ....... 140
Exhibit 91: Key Components of PBM Compensation ..................................................................................... 143
Exhibit 92: Common Pharmacy Benefit Plan Designs ..................................................................................... 147
Exhibit 93: Share of Employees Covered by a High Deductible Health Plan, 2006 to 2019 ........................... 148
Exhibit 94: Distribution of Cost Sharing Formulas for Prescription Drug Benefits in Employer-Sponsored Plans, by Plan Type, 2019 ................................................................. 148
Exhibit 95: Type of Cost Sharing for Prescription Drug Benefits, Employer-Sponsored Plans Without High Deductibles, by Benefit Tier, 2019 ................................................................. 149
Exhibit 96: Type of Cost Sharing for Prescription Drug Benefits, Employer-Sponsored Plans With High Deductibles, by Benefit Tier, 2019 ........................................................................ 149
Exhibit 97: Average Cost Sharing by Prescription Drug Tier, Employer-Sponsored Plans, 2019 .................. 150
Exhibit 98: Distribution of Coinsurance Structures for Prescription Drug Benefits, Employer-Sponsored Plans, Fourth and Specialty Tiers, 2019 .......................................................... 151
Exhibit 99: Percentage of Covered Workers With a Separate Prescription Drug Deductible, by Plan Type, 2019 ... 152
Exhibit 133: Share of Large Employers with Narrow Retail Pharmacy Network, 2013 to 2019 ........................................... 190
Exhibit 134: Mandatory Mail Pharmacy Utilization for Maintenance Medications, Employer-Sponsored Plans, 2013 to 2018 .................................................. 192
Exhibit 135: TRICARE, Net Spending on Outpatient Prescriptions, by Dispensing Outlet, 2012 to 2018 .................. 192
Exhibit 137: Payers’ Perceived Lowest-Cost Site of Care for Specialty Dispensing, 2018 ................................. 195
Exhibit 139: Oral Oncology Agents, by Dispensing Channel, 2009 vs. 2019 ................................................................. 196
Exhibit 140: Drug Sourcing for In-Practice Administration, by Practice Type and Source, 2018 .............................. 198
Exhibit 141: Drug Sourcing for In-Practice Administration, Physician Offices, 2010 vs. 2018 ................................. 199
Exhibit 142: Payer Methodologies for Computing a Pharmacy’s Estimated Acquisition Cost .......................... 203
Exhibit 143: AWP Reimbursement and Copayments for Brand-Name Prescriptions, by Dispensing Format, 2018 ... 206
Exhibit 144: AWP Reimbursement Difference, Retail vs. Mail Pharmacies, 2008 to 2018 ................................. 207
Exhibit 146: AWP Reimbursement and Copayments for Generic Prescriptions, by Dispensing Format, 2018 .... 209
Exhibit 147: Pharmacy Reimbursement Methodology and Dispensing Fee, Largest Fee-for-Service State Medicaid Programs, 2019 ................................................................. 214
Exhibit 148: Percentage of Employers Receiving No Rebates for Brand and Specialty Drugs, 2014 vs. 2019 .... 216
Exhibit 149: PBM Rebate Arrangements for Traditional Medications in Employer-Sponsored Plans, by Employer Size, 2014 vs. 2019 ................................................................. 216
Exhibit 150: PBM Rebate Arrangements for Specialty Medications in Employer-Sponsored Plans, by Employer Size, 2014 vs. 2019 ................................................................. 217
Exhibit 151: CVS Health, Brand-Name Rebates Per Commercial Life and Share Retained by PBM, 2011 to 2019 .. 219
Exhibit 152: Total PBM-Negotiated Rebates and Share Retained, Diabetes Drugs in Nevada, 2017 to 2018 ........... 219
Exhibit 153: Medicare Part D, Direct and Indirect Remuneration (DIR) as a Percentage of Total Gross Drug Spending, Medicare Part D, 2011 to 2019 ................................................................. 221
Exhibit 154: Medicare Part D, Direct and Indirect Remuneration (DIR), by Source, 2013 vs. 2019 ....................... 222
Exhibit 155: Medicaid Program, Gross Spending and Prescriptions, Fee-For-Service vs. Managed Care, 2018 .... 225
Exhibit 156: Medicaid, Gross vs. Net Spending on Outpatient Drugs, 2015 to 2018 ................................................................. 226
Exhibit 157: Price Changes for Brand-Name Drugs, List vs. Net Price Growth, 2014 to 2019 ................................. 227
Exhibit 158: Change in List vs. Net Price, by Manufacturer, 2018 ................................................................. 228
Exhibit 159: Total Value of Pharmaceutical Manufacturers’ Gross-to-Net Reductions for Brand-Name Drugs, 2014 to 2019 ................................................................. 230
Exhibit 160: Total Value of Pharmaceutical Manufacturers’ Gross-to-Net Reductions for Brand-Name Drugs, by Source, 2019 ................................................................. 231
Exhibit 161: Employers’ Use of Formulary Rebates, 2017 ..................................................................................... 233
Exhibit 162: Large Employers’ Point-of-Sale Rebate Programs, 2019 to 2022 ................................................................. 234
Exhibit 194: Source of Payment for Outpatient Prescription Drug Expenditures, 2024 .......................................................... 289
Exhibit 195: Total Brand Revenues Lost to Generic Launches, by Product Type, 2014 to 2023 .............................................. 290
Exhibit 196: Pharmacy Industry Prescription Revenues, Traditional vs. Specialty Drugs, 2014 to 2024 .......................... 291
Exhibit 197: Median Generic Price Relative to Brand Price Before Generic Entry, by Number of Manufacturers ... 294
Exhibit 198: Gleevec, Average Pharmacy Acquisition Cost, Brand vs. Generic, 2016 to 2020 .............................................. 295
Exhibit 199: Average Year-Over-Year Change in Pricing of Mature Generic Drugs, Oral vs. Injectable, 2015 to 2020 ........................................................................................................................................................................... 296
Exhibit 200: Generic Drug Approvals, FDA, 2014 to 2019 .............................................................................................................................. 298
Exhibit 201: FDA-Approved Biosimilars, Patient-Administered Drugs, 2016 to 2019 ............................................................ 300
Exhibit 202: Consumer Interest in Obtaining Prescriptions from Amazon, by Usual Dispensing Format, 2018 ...... 312
Exhibit 203: Venture Capital-Backed Online Pharmacies, 2020 ........................................................................................................... 314